![]() |
![]() |
![]() |
![]() |
![]() |
![]() |


Principal Investigator
Andreas Krämer graduated with a diploma in Chemistry from the University of Freiburg in 2012. During his PhD thesis at the University of Darmstadt (2013-2017), he focused on structural studies of bacterial members of the histone deacetylase superfamily (HDAC). After completing his PhD, he joined the group led byStefan Knapp at the SGC Frankfurt as a postdoc, where he was funded by the Wellcome Trust, working on the structure-based development of selective and potent CaMK1D kinase inhibitors for the treatment of highly aggressive subtypes of breast cancer. Afterwards he worked at the Frankfurt Cancer Institute (FCI) as a staff scientist where, among other things, he was responsible for developing a comprehensive screening platform for kinases. In the beginning of 2022, Andreas became aprincipal investigato rand is responsible for running the X-ray crystallography facility unit. His current research interests focus primarily on the structural biology of kinases and E3 ligases.
Publications AKramer
Eur J Med Chem. 2020 208:112770. doi: 10.1016/j.ejmech.2020.112770
PMID: 32883634
J. Med. Chem.. 2019 . doi: 10.1021/acs.jmedchem.9b00445
PMID: 31436984
2023
ACS Chem Biol. 21.03.2023 . doi: 10.1021/acschembio.2c00877
PMID: 36944371
Acta Pharm Sin B. 07.03.2023 13(2):709-721. doi: 10.1016/j.apsb.2022.07.016
PMID: 36873168
2022
Eur J Med Chem. 30.12.2022 249:115043. doi: 10.1016/j.ejmech.2022.115043
PMID: 36736152
J Med Chem. 14.12.2022 . doi: 10.1021/acs.jmedchem.2c01705
PMID: 36516476
Int J Mol Sci. 27.11.2022 23(23):. doi: 10.3390/ijms232314834
PMID: 36499165
J Med Chem. 16.11.2022 . doi: 10.1021/acs.jmedchem.2c01041
PMID: 36384036
Biochem Pharmacol. 27.07.2022 204:115191. doi: 10.1016/j.bcp.2022.115191
PMID: 35907497
J Med Chem. 24.05.2022 . doi: 10.1021/acs.jmedchem.2c00173
PMID: 35608370
J Org Chem. 18.02.2022 . doi: 10.1021/acs.joc.1c03057
PMID: 35179025
Int J Mol Sci. 11.01.2022 23(2):. doi: 10.3390/ijms23020763
PMID: 35054947
2021
J Med Chem. 24.11.2021 . doi: 10.1021/acs.jmedchem.1c01331
PMID: 34818007
J Med Chem. 13.05.2021 . doi: 10.1021/acs.jmedchem.1c00146
PMID: 33980013
Oncogene. 03.05.2021 . doi: 10.1038/s41388-021-01781-x
PMID: 33941852
Cell Chem Biol. 11.01.2021 . doi: 10.1016/j.chembiol.2020.12.013
PMID: 33484635
2020
J Med Chem. 10.12.2020 63(23):14680-14699. doi: 10.1021/acs.jmedchem.0c01242
PMID: 33216538
Scientific Data. 01.12.2020 7:-. doi: 10.1038/s41597-020-00642-8
PMID: 33046718
Eur J Med Chem. 20.08.2020 208:112721. doi: 10.1016/j.ejmech.2020.112721
PMID: 33035818
Eur J Med Chem. 23.08.2020 208:112770. doi: 10.1016/j.ejmech.2020.112770
PMID: 32883634
J. Med. Chem.. 20.05.2020 . doi: 10.1021/acs.jmedchem.9b01803
PMID: 32433887
ACS Chem Biol. 20.03.2020 15(3):657-668. doi: 10.1021/acschembio.9b00748
PMID: 31990523
2019
Nat Commun. 28.10.2019 10(1):4910. doi: 10.1038/s41467-019-12711-7
PMID: 31659163
J. Med. Chem.. 22.08.2019 . doi: 10.1021/acs.jmedchem.9b00445
PMID: 31436984
Nat Commun. 23.04.2019 10(1):1915. doi: 10.1038/s41467-019-09672-2
PMID: 31015424
2009
Biochem. J.. 1.3.2009 418(2):379-90. doi: 10.1042/BJ20081318
PMID: 18954305